At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 119 enrolled
Drug / intervention
Zanubrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
In Brief
A Phase 1 clinical trial evaluating Zanubrutinib and Obinutuzumab for B-cell Lymphoid Malignancies. Completed, enrolled 119 participants across 14 sites in 3 countries.
Detailed Summary
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in combination with obinutuzumab in participants with B-cell lymphoid malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Lymphoid Malignancies
CountriesAustralia, South Korea, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJan 2016
Primary CompletionSep 2020
TodayJul 2026
First PostedOct 6, 2015
Enrollment StartJan 13, 2016
Primary CompletionSep 2, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.7 years ago
Interventions
Zanubrutinibdrug
Obinutuzumabdrug